Astrazeneca
Anglo-Swedish pharma major with a deep oncology and respiratory pipeline.
Coverage of Astrazeneca is holding steady : 4 signals on the latest tracked day, level with its three-week baseline of 4, across 4 domains. That makes it the #142 most-covered of the 173 concerns we track.
Astrazeneca is steady by its own history. Its normal rhythm is about 4 signals a day across 4 domains. A real move would be a day at 5+ signals — 25% above that baseline, the bar our trend read calls accelerating — or a spread into domains beyond its usual 4. That is the move that would push it up the Wire. It sits on our Health & Bio Desk.
What’s changed
- Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca
- AstraZeneca spells out a community cancer screening strategy with the YMCA
- AstraZeneca pens $1.7B kidney drug discovery pact with go-to Chinese partner CSPC